{"id":49683,"date":"2022-10-17T14:02:15","date_gmt":"2022-10-17T12:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/"},"modified":"2022-10-17T14:02:15","modified_gmt":"2022-10-17T12:02:15","slug":"surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/","title":{"rendered":"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Funding will be used to accelerate development of the SURGE\u2122 intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its first two programs.<\/i>\n<\/li>\n<\/ul>\n<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/SeriesA?src=hash\" target=\"_blank\" rel=\"noopener\">#SeriesA<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fsurgetx.com%2F&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=SURGE+Therapeutics&amp;index=1&amp;md5=cfa6d4ce08fcbf5605077885417ea871\" rel=\"nofollow noopener\" shape=\"rect\">SURGE Therapeutics<\/a> (SURGE) today announced the completion of a $26 million Series A financing led by <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.camford.vc%2F&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=Camford+Capital&amp;index=2&amp;md5=0c2686764cd8aebe7f37527c365614a1\" rel=\"nofollow noopener\" shape=\"rect\">Camford Capital<\/a>, with participation from <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.khoslaventures.com%2F&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=Khosla+Ventures&amp;index=3&amp;md5=f987861212f11fff04ba6e07a894a09f\" rel=\"nofollow noopener\" shape=\"rect\">Khosla Ventures<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fventures.intuitive.com%2F&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=Intuitive+Ventures&amp;index=4&amp;md5=a116042499cc6bf3c0f051f16bbe9a1c\" rel=\"nofollow noopener\" shape=\"rect\">Intuitive Ventures<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pitango.com%2F&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=Pitango+HealthTech&amp;index=5&amp;md5=7c1a737e0dc907f5e2ae74da8fe3d67d\" rel=\"nofollow noopener\" shape=\"rect\">Pitango HealthTech<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2F8vc.com%2F&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=8VC&amp;index=6&amp;md5=4159be52183373a3d05aacbdb4a238b6\" rel=\"nofollow noopener\" shape=\"rect\">8VC<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.av.vc%2F&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=Alumni+Ventures&amp;index=7&amp;md5=c8e14807d8c6cb7a25367555f2c77c43\" rel=\"nofollow noopener\" shape=\"rect\">Alumni Ventures<\/a>, and the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cancerresearch.org%2Fen-us&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=Cancer+Research+Institute&amp;index=8&amp;md5=5452fd58d97ec99c1553c35b0125d636\" rel=\"nofollow noopener\" shape=\"rect\">Cancer Research Institute<\/a>. The funds will be used to accelerate development of the SURGE\u2122 intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its injectable biodegradable hydrogel.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221017005003\/en\/1596257\/5\/SURGE_No_Slogan_-_COLOUR.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221017005003\/en\/1596257\/21\/SURGE_No_Slogan_-_COLOUR.jpg\"><\/a><\/p>\n<p>\nWhile surgery is the standard of care for patients with solid tumors, surgery can lead to the return and spread of the cancer. Such recurrence and metastasis are very challenging to treat, so the ability to prevent them from manifesting would be highly desirable. To this end, SURGE is developing immunotherapies that can be injected directly into the site of tumor resection (intraoperative immunotherapy), to improve cancer patient survival and, ultimately, the standard of care.\n<\/p>\n<p>\nBuilt upon <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fstm.sciencemag.org%2Fcontent%2F10%2F433%2Feaar1916.long&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=groundbreaking+research&amp;index=9&amp;md5=d274e53f080796c7c15ed93a2a4f153b\" rel=\"nofollow noopener\" shape=\"rect\">groundbreaking research<\/a> conducted in founder and CEO Dr. Michael Goldberg&#8217;s laboratory at Harvard Medical School, the SURGE Therapeutics\u2122 injectable biodegradable hydrogel enables extended, localized release of cancer immunotherapy at the site of surgical tumor resection. In multiple aggressive murine models of metastasizing cancer, intraoperative immunotherapy <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fstm.sciencemag.org%2Fcontent%2F10%2F433%2Feaar1916.long&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=vastly+improved+survival+benefit&amp;index=10&amp;md5=7c6e93e8d19e19f03607b214998b7ecd\" rel=\"nofollow noopener\" shape=\"rect\">vastly improved survival benefit<\/a> relative to traditional routes of administration, whether systemic or local. Dr. Goldberg completed his PhD and post-doctoral training at MIT under the mentorship of Robert Langer and Phillip Sharp, respectively.\n<\/p>\n<p>\nThe proprietary hydrogel has been shown to reduce post-surgical recurrence and metastasis, which account for 90 percent of cancer-related deaths and have been linked to the immune suppression caused by surgery. Reprogramming the body\u2019s response to surgery from immunosuppressive to immunostimulatory can trigger the patient\u2019s immune system to destroy both local and distal residual cancer cells, reducing recurrence and improving survival.\n<\/p>\n<p>\n\u201cSURGE seeks to radically redefine the process of care for cancer patients, creating a simple and effective treatment that could potentially be administered during any surgical oncology procedure. SURGE\u2019s novel approach has the potential to usher in a new pillar of cancer immunotherapy that could markedly enhance survival outcomes,\u201d said Robert Langer, Chair of the Scientific Advisory Board, SURGE Therapeutics.\n<\/p>\n<p>\n\u201cEven after a tumor has been removed, it is common for a small number of cancer cells to remain behind, whether at the site of the primary tumor or elsewhere in the body. Indeed, 40% of cancer patients who undergo surgery relapse within five years, so this is a major unmet medical need,\u201d said Dr. Michael Goldberg, CEO &amp; Founder of SURGE Therapeutics. \u201cI left my faculty position at Harvard to focus full-time on developing this innovation, which we believe will improve the standard of care for cancer patients. The Series A financing enables us to advance our proprietary intraoperative immunotherapies into clinical trials so that nobody has to grieve the loss of a loved one owing to cancer recurrence after surgery.\u201d\n<\/p>\n<p>\n\u201cAt Intuitive Ventures, we look for companies taking minimally invasive care to the next level \u2013 SURGE is in the process of putting powerful immunotherapies into the hands of surgeons at a moment of great potential impact for cancer patients,\u201d said Dr. Oliver Keown, M.D., Managing Director of Intuitive Ventures. \u201cWe are excited to work alongside Michael and his world-class team as they pioneer the field of localized therapeutics strategically placed and timed to enhance treatment for cancer patients.\u201d\n<\/p>\n<p>\nSURGE has a team of operators and advisors that include leaders in localized therapeutics, drug delivery, translational immunotherapy, surgical oncology, drug development, and immune-engineering: Charles (\u201cChuck\u201d) Carignan, MD (former Chief Medical Officer of Boston Scientific), Robert Langer, ScD (founder of Moderna), Elizabeth Jaffee, MD (Past-President of the American Association for Cancer Research), Timothy Eberlein, MD (Past-President of the Society of Surgical Oncology), Francis Cuss, MD (former Chief Scientific Officer of Bristol Myers Squibb), and Darrell Irvine, PhD (HHMI Investigator).\n<\/p>\n<p>\nThe SURGERx\u2122 platform is designed to improve the efficacy and safety of immunotherapy treatment, concentrating 100 percent of the effective dose where and when it can yield tremendous impact. It also increases the number of addressable patients for highly potent molecules that are currently limited to treatment of accessible lesions via intratumoral injection.\n<\/p>\n<p>\n<b>About SURGE Therapeutics<\/b>\n<\/p>\n<p>\nSURGE Therapeutics (The Intraoperative Immunotherapy Company\u2122) seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed. The company is developing an injectable biodegradable hydrogel that enables extended, localized release of cancer immunotherapy at the site of surgical tumor resection to improve patient survival outcomes. SURGE is based in Cambridge, MA. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fsurgetx.com%2F&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=http%3A%2F%2Fsurgetx.com&amp;index=11&amp;md5=12ddd4b2b750d8f7694b14b69c78d877\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/surgetx.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsurge-therapeutics&amp;esheet=52940276&amp;newsitemid=20221017005003&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=12&amp;md5=d9f4840380a2426ebb6fdda3adb32196\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p>\nSURGE, SURGE Therapeutics, SURGERx, and The Interoperative Immunotherapy Company are trademarks of SURGE Therapeutics, Inc.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nKimberly Ha<br \/>\n<br \/>KKH Advisors<br \/>\n<br \/>917-291-5744<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x6b;&#105;&#109;&#98;&#101;&#114;&#108;&#121;&#46;ha&#64;&#x6b;&#x6b;&#x68;&#x61;&#x64;&#x76;&#x69;&#x73;&#x6f;&#114;&#115;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6b;&#105;m&#x62;&#101;r&#x6c;&#121;&#46;&#x68;&#x61;&#64;&#x6b;&#x6b;&#104;a&#x64;&#118;i&#x73;&#111;r&#x73;&#x2e;&#99;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Funding will be used to accelerate development of the SURGE\u2122 intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its first two programs. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;#SeriesA&#8212;SURGE Therapeutics (SURGE) today announced the completion of a $26 million Series A financing led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49683","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Funding will be used to accelerate development of the SURGE\u2122 intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its first two programs. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;#SeriesA&#8212;SURGE Therapeutics (SURGE) today announced the completion of a $26 million Series A financing led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-17T12:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221017005003\/en\/1596257\/21\/SURGE_No_Slogan_-_COLOUR.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery\",\"datePublished\":\"2022-10-17T12:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/\"},\"wordCount\":818,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221017005003\\\/en\\\/1596257\\\/21\\\/SURGE_No_Slogan_-_COLOUR.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/\",\"name\":\"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221017005003\\\/en\\\/1596257\\\/21\\\/SURGE_No_Slogan_-_COLOUR.jpg\",\"datePublished\":\"2022-10-17T12:02:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221017005003\\\/en\\\/1596257\\\/21\\\/SURGE_No_Slogan_-_COLOUR.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221017005003\\\/en\\\/1596257\\\/21\\\/SURGE_No_Slogan_-_COLOUR.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/","og_locale":"en_US","og_type":"article","og_title":"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery - Pharma Trend","og_description":"Funding will be used to accelerate development of the SURGE\u2122 intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its first two programs. CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;#SeriesA&#8212;SURGE Therapeutics (SURGE) today announced the completion of a $26 million Series A financing led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-17T12:02:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221017005003\/en\/1596257\/21\/SURGE_No_Slogan_-_COLOUR.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery","datePublished":"2022-10-17T12:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/"},"wordCount":818,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221017005003\/en\/1596257\/21\/SURGE_No_Slogan_-_COLOUR.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/","url":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/","name":"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221017005003\/en\/1596257\/21\/SURGE_No_Slogan_-_COLOUR.jpg","datePublished":"2022-10-17T12:02:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221017005003\/en\/1596257\/21\/SURGE_No_Slogan_-_COLOUR.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221017005003\/en\/1596257\/21\/SURGE_No_Slogan_-_COLOUR.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/surge-therapeutics-raises-26m-series-a-financing-to-accelerate-development-of-intraoperative-immunotherapy-to-improve-survival-outcomes-post-surgery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49683"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49683\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}